Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03500796

Enrollment

Registered

2018-04-18

Start date

2018-04-15

Completion date

2020-12-31

Last updated

2021-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Perforation

Brief summary

Use of amniotic membrane(AMT) and platelet rich plasma (PRP) clot for closure of central corneal perforation

Detailed description

Use of amniotic membrane and platelet rich plasma clot for closure of central corneal perforation either post infective or posttraumatic

Interventions

PROCEDUREPlatelet rich plasma clot implantation

Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane

PROCEDUREWound closure with amniotic membrane

Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* central corneal perforation

Exclusion criteria

* active infection * posterior segment pathology * non seeing eye

Design outcomes

Primary

Measure	Time frame	Description
Closure of the corneal wound	3 months	sealing of the edges corneal gap, with formation of scar tissue

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026